Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

Open in Screener

SVRA

Savara Inc

Jan 02 • 04:00PM ET

3.07

Dollar change 0.00
Percentage change 0.00	%

Healthcare • Biotechnology • USA • NASD

Peers: BMRN RARE ARWR NVAX AXSM HRTX ACAD PTGX KPTI CRBP

| Held by: VTI IWM VXF XBI IWO VTWO SCHA IBB VHT ESML

Index	RUT	P/E	-	EPS (ttm)	-0.44	Insider Own	48.29%	Shs Outstand	170.84M	Perf Week	-4.06%
Market Cap	526.87M	Forward P/E	-	EPS next Y	-0.49	Insider Trans	0.04%	Shs Float	88.75M	Perf Month	-7.11%
Income	-82.94M	PEG	-	EPS next Q	-0.11	Inst Own	52.21%	Short Float	14.56%	Perf Quarter	-21.28%
Sales	0.00M	P/S	-	EPS this Y	-39.77%	Inst Trans	15.71%	Short Ratio	9.11	Perf Half Y	-29.10%
Book/sh	1.17	P/B	2.63	EPS next Y	-5.42%	ROA	-39.41%	Short Interest	12.92M	Perf Year	-29.75%
Cash/sh	1.28	P/C	2.40	EPS next 5Y	-	ROE	-47.95%	52W Range	2.82 - 5.70	Perf YTD	0.00%
Dividend Est.	-	P/FCF	-	EPS past 5Y	29.09%	ROI	-36.71%	52W High	-46.14%	Beta	0.68
Dividend TTM	-	Quick Ratio	17.70	Sales past 5Y	-25.00%	Gross Margin	-	52W Low	9.06%	ATR (14)	0.19
Dividend Ex-Date	-	Current Ratio	17.70	EPS Y/Y TTM	-39.95%	Oper. Margin	-	RSI (14)	40.92	Volatility	4.52% 6.29%
Employees	37	Debt/Eq	0.13	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.25	Target Price	9.56
Option/Short	Yes / Yes	LT Debt/Eq	0.13	EPS Q/Q	-13.37%	Payout	-	Rel Volume	0.50	Prev Close	3.07
Sales Surprise	-	EPS Surprise	-1.29%	Sales Q/Q	-	Earnings	Nov 12 BMO	Avg Volume	1.42M	Price	3.07
SMA20	-6.66%	SMA50	-9.78%	SMA200	-25.86%	Trades		Volume	712,967	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-20-24	Initiated	Wells Fargo	Overweight	$8
Nov-13-24	Downgrade	Evercore ISI	Outperform → In-line	$7 → $5
Feb-15-24	Initiated	JMP Securities	Mkt Outperform	$8
Nov-07-23	Initiated	Guggenheim	Buy	$7
May-16-23	Upgrade	Jefferies	Hold → Buy	$2 → $4
Mar-31-23	Downgrade	Jefferies	Buy → Hold	$2
Mar-16-21	Initiated	Piper Sandler	Overweight	$7
Mar-15-21	Initiated	Oppenheimer	Outperform	$4
Jun-13-19	Reiterated	H.C. Wainwright	Buy	$22 → $6
Jun-13-19	Downgrade	Ladenburg Thalmann	Buy → Neutral	$21 → $3
Jun-13-19	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Aug-13-18	Resumed	ROTH Capital	Neutral	$12
Jan-03-18	Initiated	Ladenburg Thalmann	Buy	$35
Sep-27-17	Resumed	ROTH Capital	Buy	$40
Sep-22-17	Initiated	Jefferies	Buy	$20
Sep-11-17	Initiated	JMP Securities	Mkt Outperform	$20

Show Previous Ratings

Dec-23-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Dec-18-24 04:05PM	Savara Initiates Rolling Submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (Business Wire) -6.21% +6.95%
Dec-17-24 04:05PM	Savara Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire)
Nov-22-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
08:05AM	Savara Announces Encore Presentation of Results from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the British Thoracic Society Winter Meeting 2024 (Business Wire)
01:21PM	Loading…
Nov-13-24 01:21PM	Evercore Downgrades Savara on Manufacturing Concerns for Lung Disease Drug Candidate (GuruFocus.com) -15.14%
08:05AM	Savara Announces Participation in Upcoming Healthcare Conferences (Business Wire)
Nov-12-24 08:05AM	Savara Reports Third Quarter 2024 Financial Results and Provides Business Update (Business Wire) -5.90%
Nov-04-24 04:05PM	Savara to Present at the Guggenheim Inaugural Healthcare Innovation Conference (Business Wire)
Oct-22-24 08:05AM	Savara Announces the Rare Lung Disease, Autoimmune Pulmonary Alveolar Proteinosis (aPAP), is Highlighted on a New Episode of The Balancing Act Airing on Lifetime TV (Business Wire)
Oct-18-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire) -5.05%
Oct-01-24 08:05AM	Savara Announces Patient Journey Map for People Living with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Accepted for Poster Presentation at the CHEST 2024 Annual Meeting (Business Wire) -5.90%
Sep-27-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
08:05AM	Savara Announces Expanded Access Program (EAP) for Molgramostim Inhalation Solution (Molgramostim) for Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (Business Wire)
Sep-24-24 08:05AM	Savara Appoints Braden Parker as Chief Commercial Officer, Effective Immediately (Business Wire)
08:05AM	Loading…
Sep-23-24 08:05AM	Savara to Host Analyst and Investor Webinar on September 30, 2024 (Business Wire)
Sep-08-24 06:45AM	Savara Announces New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Were Presented at the European Respiratory Society (ERS) Congress 2024 (Business Wire)
Sep-06-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Sep-03-24 04:05PM	Savara to Present at the H.C. Wainwright 26th Annual Global Investment Conference (Business Wire)
Sep-01-24 10:26PM	Savara, Inc. (SVRA): The Best Multibagger Penny Stock of 2025? (Insider Monkey)
Aug-29-24 08:41PM	10 Best Multibagger Penny Stocks of 2025 (Insider Monkey)
Aug-16-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Aug-15-24 08:05AM	Savara to Present New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2024 (Business Wire) +5.87%
Aug-12-24 04:05PM	Savara Reports Second Quarter 2024 Financial Results and Provides Business Update (Business Wire)
Jun-29-24 08:35PM	Did Savara Inc. (SVRA) Receive a Good Rating from Wall Street Analysts in Q1? (Insider Monkey)
06:30PM	10 Best Biotech Penny Stocks to Buy Now (Insider Monkey)
Jun-28-24 08:50AM	Savara Announces Pricing of $100.0 Million Underwritten Offering of Common Stock (Business Wire) +5.77%
Jun-26-24 07:41AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace)
06:30AM	Savara Announces Molgramostim Nebulizer Solution (Molgramostim) Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2, a Pivotal Phase 3 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (Business Wire)
Jun-25-24 08:05PM	Savara to Host Investor Call to Discuss Top Line Results From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (Business Wire)
09:00AM	Loading…
Jun-19-24 09:00AM	3 Penny Stocks Poised for Major Upside Over the Next 5 Years (InvestorPlace)
Jun-11-24 06:00AM	3 Penny Stocks That Can Deliver Over 5,000% Upside by 2025: June Edition (InvestorPlace)
May-29-24 08:05AM	Savara to Present at the Jefferies Global Healthcare Conference (Business Wire)
May-21-24 08:20AM	Oppenheimer Adjusts Savara Price Target to $11 From $9.50, Maintains Outperform Rating (MT Newswires)
May-19-24 12:15PM	Savara Presented New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024 (Business Wire)
May-16-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire) -5.08%
May-09-24 10:55PM	SVRA Stock Earnings: Savara Misses EPS for Q1 2024 (InvestorPlace) -8.19%
04:05PM	Savara Reports First Quarter 2024 Financial Results and Provides Business Update (Business Wire)
May-07-24 04:05PM	Savara to Present at the Citizens JMP Life Sciences Conference (Business Wire) +6.26% -5.13%
Apr-08-24 08:05AM	Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024 (Business Wire)
Mar-22-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Mar-07-24 10:54PM	SVRA Stock Earnings: Savara Beats EPS for Q4 2023 (InvestorPlace) -5.19%
04:05PM	Savara Reports Fourth Quarter/Year-End 2023 Financial Results and Provides Business Update (Business Wire)
Mar-06-24 04:05PM	Savara to Present at the Barclays 26th Annual Global Healthcare Conference (Business Wire)
Feb-02-24 08:05AM	Savara Announces New Employment Inducement Grant (Business Wire)
Jan-31-24 08:05AM	Savara to Present at Two Upcoming Healthcare Conferences (Business Wire)
Dec-30-23 03:01PM	Insider Sell: CEO Matthew Pauls Disposes of 84,000 Shares of Savara Inc (SVRA) (GuruFocus.com)
Dec-21-23 08:05AM	Savara Introduces aPAP ClearPath, a GM-CSF Autoantibody Blood Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (Business Wire)
Dec-20-23 08:05AM	Savara Added to the NASDAQ Biotechnology Index (Business Wire)
Dec-15-23 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Nov-21-23 08:05AM	Savara to Present at the Piper Sandler 35th Annual Healthcare Conference (Business Wire)
Nov-09-23 04:05PM	Savara Reports Third Quarter Financial Results and Provides Business Update (Business Wire) -7.84%
Nov-08-23 04:05PM	Savara to Present at the Jefferies London Healthcare Conference (Business Wire)
Oct-06-23 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Sep-27-23 07:29PM	3 Penny Stocks to Provide 1,000% Returns Over the Next Decade (InvestorPlace)
Sep-17-23 10:54AM	15 Penny Stocks with Biggest Upside (Insider Monkey)
Sep-12-23 09:12AM	The 3 Best Penny Stocks to Buy Now: September 2023 (InvestorPlace)
Sep-05-23 04:05PM	Savara to Present at the H.C. Wainwright 25th Annual Global Investment Conference (Business Wire)
Aug-10-23 04:05PM	Savara Reports Second Quarter Financial Results and Provides Business Update (Business Wire)
Aug-04-23 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Jul-13-23 07:00AM	Savara Announces Pricing of $80 Million Underwritten Offering of Common Stock and Pre-Funded Warrants (Business Wire) +8.92%
Jun-26-23 04:05PM	Savara Added to Russell 3000® Index (Business Wire) -7.34%
08:05AM	Savara Completes Enrollment of Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (Business Wire)
Jun-02-23 08:05AM	Savara to Present at the Jefferies Healthcare Conference (Business Wire)
May-28-23 08:26AM	Independent Director of Savara David Ramsay Buys 4.8% More Shares \ (Simply Wall St.)
May-16-23 12:32PM	Why Shares of Savara Jumped on Tuesday (Motley Fool) +9.09%
May-15-23 08:05AM	Savara Reports First Quarter Financial Results and Provides Business Update (Business Wire)
May-05-23 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire) +6.84%
Apr-03-23 07:33AM	Savara Inc. (NASDAQ:SVRA) Is Expected To Breakeven In The Near Future (Simply Wall St.) -6.15%
Mar-31-23 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Mar-30-23 04:05PM	Savara Reports Fourth Quarter / Year-End 2022 Financial Results and Provides Business Update (Business Wire)
Mar-20-23 06:35AM	Daily Vickers Top Insider Picks for 03/20/2023 (Argus Research)
Mar-17-23 06:47AM	Daily Vickers Top Insider Picks for 03/17/2023 (Argus Research) -7.31%
Mar-16-23 06:51AM	Daily Vickers Top Insider Picks for 03/16/2023 (Argus Research)
Mar-15-23 06:44AM	Daily Vickers Top Insider Picks for 03/15/2023 (Argus Research)
Mar-13-23 06:32AM	Daily Vickers Top Insider Picks for 03/13/2023 (Argus Research)
Mar-10-23 07:04AM	Daily Vickers Top Insider Picks for 03/10/2023 (Argus Research) -15.94%
Mar-09-23 06:33AM	Daily Vickers Top Insider Picks for 03/09/2023 (Argus Research)
Mar-08-23 06:30AM	Daily Vickers Top Insider Picks for 03/08/2023 (Argus Research)
Mar-07-23 06:34AM	Daily Vickers Top Insider Picks for 03/07/2023 (Argus Research)
Mar-06-23 04:05PM	Savara to Present at the Oppenheimer 33rd Annual Healthcare Conference (Business Wire)
07:22AM	Daily Vickers Top Insider Picks for 03/06/2023 (Argus Research)
Mar-03-23 06:38AM	Daily Vickers Top Insider Picks for 03/03/2023 (Argus Research) -7.42%
Mar-02-23 06:44AM	Daily Vickers Top Insider Picks for 03/02/2023 (Argus Research)
Mar-01-23 06:01AM	Daily Vickers Top Insider Picks for 03/01/2023 (Argus Research)
Feb-28-23 04:05PM	Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
06:43AM	Daily Vickers Top Insider Picks for 02/28/2023 (Argus Research)
Feb-27-23 06:50AM	Daily Vickers Top Insider Picks for 02/27/2023 (Argus Research)
Feb-23-23 07:21AM	Daily Vickers Top Insider Picks for 02/23/2023 (Argus Research)
Feb-22-23 06:56AM	Daily Vickers Top Insider Picks for 02/22/2023 (Argus Research)
Feb-21-23 07:35AM	Daily Vickers Top Insider Picks for 02/21/2023 (Argus Research)
Feb-17-23 06:27AM	Daily Vickers Top Insider Picks for 02/17/2023 (Argus Research)
Feb-16-23 07:28AM	Daily Vickers Top Insider Picks for 02/16/2023 (Argus Research)
Feb-15-23 07:01AM	Daily Vickers Top Insider Picks for 02/15/2023 (Argus Research) +6.52%
06:24AM	Savara Inc. (NASDAQ:SVRA) insiders placed bullish bets worth US$858k in the last 12 months (Simply Wall St.)
Feb-14-23 08:05AM	Savara Announces New Leadership Appointments (Business Wire)
06:23AM	Daily Vickers Top Insider Picks for 02/14/2023 (Argus Research)
Feb-13-23 07:30AM	Daily Vickers Top Insider Picks for 02/13/2023 (Argus Research)
Feb-10-23 06:42AM	Daily Vickers Top Insider Picks for 02/10/2023 (Argus Research)
Feb-09-23 06:51AM	Daily Vickers Top Insider Picks for 02/09/2023 (Argus Research)

Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its program includes molgramostim, which is an inhaled formulation of recombinant human GM-CSF and being developed for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in December 1995 and is headquartered in Langhorne, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lowrance David L	Chief Financial Officer	Dec 16 '24	Sale	3.33	25,000	83,278	381,005	Dec 16 05:59 PM
Pauls Matthew	CHIEF EXECUTIVE OFFICER	Dec 16 '24	Sale	3.31	54,702	180,828	1,536,379	Dec 16 05:56 PM
Hawkins Richard J	Director	Dec 16 '24	Sale	3.32	8,000	26,569	67,241	Dec 16 05:53 PM
Pauls Matthew	Director	Dec 16 '24	Proposed Sale	3.31	54,702	180,800		Dec 16 05:13 PM
Hawkins Richard J	Director	Dec 16 '24	Proposed Sale	3.29	8,000	26,300		Dec 16 03:15 PM
Lowrance David L	Officer	Dec 16 '24	Proposed Sale	3.30	25,000	82,500		Dec 16 03:08 PM
McCracken Joseph S	Director	Nov 19 '24	Buy	2.95	20,000	59,072	210,837	Nov 20 07:55 AM
RAMSAY DAVID A	Director	Nov 18 '24	Buy	2.88	100,000	287,600	2,323,642	Nov 18 12:33 PM

Open in Screener

PSTV

Plus Therapeutics Inc

Jan 02 • 04:00PM ET

1.18

Dollar change +0.03
Percentage change 2.61	%

Healthcare • Biotechnology • USA • NASD

PSTV Plus Therapeutics Inc daily Stock Chart

Peers: ADAP SUPN KPTI IMUX MEIP PBYI CRIS RIGL SYBX

| Held by: VXF

Index	-	P/E	-	EPS (ttm)	-2.24	Insider Own	2.55%	Shs Outstand	5.90M	Perf Week	9.26%
Market Cap	6.96M	Forward P/E	-	EPS next Y	-1.49	Insider Trans	36.11%	Shs Float	5.75M	Perf Month	-8.53%
Income	-12.88M	PEG	-	EPS next Q	-0.40	Inst Own	11.39%	Short Float	1.63%	Perf Quarter	-16.31%
Sales	5.72M	P/S	1.22	EPS this Y	54.36%	Inst Trans	-8.19%	Short Ratio	1.21	Perf Half Y	-22.88%
Book/sh	-0.88	P/B	-	EPS next Y	23.00%	ROA	-127.22%	Short Interest	0.09M	Perf Year	-36.22%
Cash/sh	0.81	P/C	1.45	EPS next 5Y	-	ROE	-522.50%	52W Range	0.93 - 2.67	Perf YTD	2.61%
Dividend Est.	-	P/FCF	-	EPS past 5Y	68.20%	ROI	-	52W High	-55.81%	Beta	0.69
Dividend TTM	-	Quick Ratio	0.44	Sales past 5Y	474.41%	Gross Margin	85.99%	52W Low	27.57%	ATR (14)	0.10
Dividend Ex-Date	-	Current Ratio	0.44	EPS Y/Y TTM	60.96%	Oper. Margin	-255.98%	RSI (14)	48.99	Volatility	7.37% 9.19%
Employees	20	Debt/Eq	-	Sales Y/Y TTM	52.63%	Profit Margin	-225.07%	Recom	1.00	Target Price	10.25
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	63.35%	Payout	-	Rel Volume	0.38	Prev Close	1.15
Sales Surprise	-0.70%	EPS Surprise	34.22%	Sales Q/Q	17.42%	Earnings	Nov 14 AMC	Avg Volume	77.74K	Price	1.18
SMA20	-1.07%	SMA50	-5.81%	SMA200	-26.86%	Trades		Volume	29,436	Change	2.61%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-25-21	Initiated	Ladenburg Thalmann	Buy	$8
Oct-16-20	Initiated	Maxim Group	Buy	$6

Dec-17-24 07:30AM	Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Breast Cancer Patients with Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium (GlobeNewswire) -8.55%
Dec-04-24 07:30AM	Plus Therapeutics to Showcase ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium (GlobeNewswire)
Dec-03-24 07:30AM	Plus Therapeutics Expands Strategic Agreement with Telix IsoTherapeutics Group for Rhenium-186 Radioisotope Supply (GlobeNewswire)
Nov-25-24 09:48AM	CNSide Diagnostics reports data from trial of CNSide CSF Assay in LM diagnosis (Medical Device Network)
07:30AM	Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 SNO Annual Conference (GlobeNewswire)
07:30AM	Loading…
Nov-22-24 07:30AM	Plus Therapeutics to Present Positive FORESEE Clinical Trial Summary Demonstrating Utility of CNSide Cerebrospinal Fluid Assay in Diagnosis and Clinical Management of Patients with Leptomeningeal Metastases (GlobeNewswire)
Nov-21-24 07:30AM	Plus Therapeutics to Present Multi-Institutional Experience Using the CNSide Cerebrospinal Fluid Assay in Patients with Leptomeningeal Metastases (GlobeNewswire)
Nov-15-24 02:16AM	Plus Therapeutics Inc (PSTV) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ... (GuruFocus.com) -7.14%
Nov-14-24 04:15PM	Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Nov-07-24 07:18AM	Plus Therapeutics partners with SpectronRx for CNS therapy development (Pharmaceutical Business Review)
Nov-06-24 07:30AM	Plus Therapeutics and SpectronRx Announce Radiotherapeutic Manufacturing Partnership (GlobeNewswire) +5.15%
Nov-05-24 07:30AM	Plus Therapeutics to Announce Third Quarter Financial Results and Host Conference Call on November 14, 2024 (GlobeNewswire)
Oct-29-24 07:30AM	Plus Therapeutics Showcases Leptomeningeal Metastases Programs at the 2024 SNO Annual Meeting in Houston, Texas (GlobeNewswire)
Oct-01-24 07:30AM	Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update at the 2024 Congress of Neurological Surgeons Annual Meeting (GlobeNewswire) -10.27%
Sep-18-24 07:30AM	Plus Therapeutics Showcases New Interim ReSPECT-GBM Phase 2 Trial Data at the 2024 Congress of Neurological Surgeons Annual Meeting (GlobeNewswire)
07:30AM	Loading…
Sep-04-24 07:30AM	Plus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Aug-15-24 09:42AM	Q2 2024 Plus Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-14-24 09:53PM	PSTV Stock Earnings: Plus Therapeutics Misses EPS, Misses Revenue for Q2 2024 (InvestorPlace)
04:16PM	Plus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Aug-13-24 07:30AM	Plus Therapeutics Presents Positive Clinical Trial Results at the 2024 SNO/ASCO CNS Metastases Conference (GlobeNewswire) +5.67%
Aug-12-24 07:30AM	Plus Therapeutics Presents Positive Interim ReSPECT-LM Phase 1 Data for Leptomeningeal Metastases at 2024 SNO/ASCO CNS Metastases Conference (GlobeNewswire)
Aug-08-24 07:30AM	Plus Therapeutics to Announce Second Quarter Financial Results and Host Conference Call on August 14, 2024 (GlobeNewswire)
Jul-25-24 07:30AM	Plus Therapeutics Showcases Leptomeningeal Metastases Programs at 2024 SNO/ASCO Conference (GlobeNewswire)
Jul-02-24 07:30AM	Plus Therapeutics to Present at the Gordon Research Conference Radionuclide Theranostics for the Management of Cancer (GlobeNewswire)
Jun-07-24 07:30AM	Plus Therapeutics Expands Management Team and Reports $3.3M Advance Payment from CPRIT (GlobeNewswire) -5.24%
May-17-24 05:00PM	Plus Therapeutics Announces New Employment Inducement Grants (GlobeNewswire)
May-16-24 03:05AM	Plus Therapeutics Inc (PSTV) Q1 2024 Earnings Call Transcript Highlights: Strategic Progress ... (GuruFocus.com)
May-15-24 08:53PM	PSTV Stock Earnings: Plus Therapeutics Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace) +6.91%
04:15PM	Plus Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
May-13-24 07:30AM	Plus Therapeutics to Announce First Quarter Financial Results and Host Conference Call on May 15, 2024 (GlobeNewswire)
11:29AM	Loading…
May-09-24 11:29AM	Plus Therapeutics Provides Highlights Regarding Leptomeningeal Metastases Acquisition and Topline Clinical Trial Data on the FORESEE Trial (GlobeNewswire)
May-08-24 05:35PM	Plus Therapeutics to Host Investor Call to Discuss Leptomeningeal Cancer Related Acquisition and Topline Clinical Trial Data from the FORESEE Trial (GlobeNewswire) +6.57%
May-06-24 07:30AM	Plus Therapeutics Announces Private Placement Financing of up to $18 Million (GlobeNewswire) +11.67%
Apr-22-24 09:00AM	Micro-Cap Brain Cancer Focused Plus Therapeutics Poised To Receive $3M From US Department of Defense (Benzinga)
07:00AM	Plus Therapeutics Receives $3 Million Award Recommendation from the United States Department of Defense (GlobeNewswire)
Apr-09-24 07:00AM	Neuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D. Join Plus' Management Team (GlobeNewswire)
Mar-27-24 08:00AM	Plus Therapeutics to Present at the National Comprehensive Cancer Network Annual Conference (GlobeNewswire)
Mar-25-24 08:00AM	Plus Therapeutics Announces Validation & Clinical Implementation of CSF-01 Leptomeningeal Cancer Cell Diagnostic (GlobeNewswire)
Mar-11-24 07:00AM	Plus Therapeutics Completes Dosing in Cohort 5 of ReSPECT-LM Phase 1 Trial of Rhenium (186Re) Obisbemeda in Leptomeningeal Metastases (GlobeNewswire)
Mar-07-24 08:59AM	Plus Therapeutics, Inc. (NASDAQ:PSTV) Q4 2023 Earnings Call Transcript (Insider Monkey) -10.59%
Mar-06-24 01:43PM	Q4 2023 Plus Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -11.24%
Mar-05-24 09:52PM	PSTV Stock Earnings: Plus Therapeutics Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace)
05:35PM	Plus Therapeutics (PSTV) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Plus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights (GlobeNewswire)
Feb-27-24 08:00AM	Plus Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on March 5, 2024 (GlobeNewswire) +6.01%
Dec-18-23 07:00AM	Plus Updates Financial and Cash Guidance for 2024 (GlobeNewswire)
Dec-12-23 08:00AM	Plus Therapeutics Partners With K2bio for Development of Novel Tests for Cerebrospinal Fluid (CSF) Tumor Cell and Molecular Biomarker Analyses (GlobeNewswire)
Nov-29-23 08:00AM	Plus Therapeutics to Present at the 5th Targeted Radiopharmaceuticals Summit Europe (GlobeNewswire) -5.56%
Nov-20-23 07:00AM	Plus Therapeutics Reports New Interim ReSPECT-GBM Phase 2 Trial Data at the Society for NeuroOncology Annual Meeting and will Host Key Opinion Leader Webinar (GlobeNewswire) -27.76%
Nov-15-23 07:00AM	Plus Therapeutics to Host Virtual KOL Event on New Phase 2 ReSPECT-GBM Data in Recurrent Glioblastoma Presented at the Society for NeuroOncology (SNO) Conference on Monday, November 20, 2023 (GlobeNewswire) +12.43%
Nov-13-23 09:31AM	Thinking about buying stock in Tivic Health Systems, Tigo Energy, TAT Technologies, Plus Therapeutics, or Acumen Pharmaceuticals? (PR Newswire)
Nov-03-23 07:00AM	Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to Rhenium (186Re) Obisbemeda for the Treatment of Breast Cancer with Leptomeningeal Metastases (GlobeNewswire) +17.65%
Nov-01-23 09:29AM	Plus Therapeutics, Inc. (NASDAQ:PSTV) Q3 2023 Earnings Call Transcript (Insider Monkey) +5.74%
Oct-31-23 04:10PM	Plus Therapeutics Announces Share Repurchase Program (GlobeNewswire) +10.92%
04:05PM	Plus Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
Oct-25-23 09:21AM	Plus Therapeutics to Present at the Society for NeuroOncology Annual Meeting and will Host Key Opinion Leader Webinar (GlobeNewswire) -7.34%
Oct-23-23 04:05PM	Plus Therapeutics to Announce Third Quarter 2023 Financial Results and Host Conference Call on October 31, 2023 (GlobeNewswire) -5.22%
Oct-10-23 07:00AM	Plus Therapeutics Completes Dosing in Cohort 4 of ReSPECT-LM Phase 1 Clinical Trial of Rhenium ( Re) Obisbemeda in Leptomeningeal Metastases (GlobeNewswire) +5.04%
Oct-09-23 07:00AM	Plus Therapeutics to Participate in the Jones Trading Healthcare Summit and ThinkEquity Conference in October (GlobeNewswire)
Sep-19-23 01:07PM	Targeted Cancer Treatment: Plus Therapeutics CEO Marc Hedrick, Live from NYSE (Exec Edge)
Sep-15-23 11:17AM	Director Howard Clowes Buys 6,993 Shares of Plus Therapeutics Inc (GuruFocus.com)
Sep-11-23 12:44PM	Plus Therapeutics Presents Cancer Treatment Data at Conference (Exec Edge) +8.70%
07:00AM	Plus Therapeutics Receives $1.9 Million Advance Payment from CPRIT and Plans to Present at the CPRIT Innovations in Cancer Prevention and Research Conference (GlobeNewswire)
Sep-08-23 12:49PM	Plus Therapeutics Expands Biocept Partnership with Diagnostic Platform (Exec Edge) -53.54%
11:18AM	Why Is Cancer Diagnostic Focused Biocept Stock Trading Higher Today? (Benzinga)
08:30AM	EXCLUSIVE: Cancer Firm Plus Therapeutics Licenses Diagnostic Assay To Detect Central Nervous System Cancers (Benzinga)
07:00AM	Plus Therapeutics Enters into License Agreement for Cerebrospinal Fluid Tumor Cell Enumeration Assay (GlobeNewswire)
Sep-05-23 01:13PM	Plus Therapeutics Trialing Cancer Treatment for Cerebrospinal Fluid (Exec Edge)
07:00AM	Plus Therapeutics Initiates Part B of ReSPECT-LM Phase 1/2a Trial for Leptomeningeal Metastase (GlobeNewswire)
Aug-30-23 07:00AM	Plus Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-18-23 09:55AM	Plus (PSTV) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks)
Aug-15-23 10:58AM	Q2 2023 Plus Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-14-23 04:05PM	Plus Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
Aug-11-23 06:28PM	Positive Results Unveiled for Targeted CNS Cancer Treatment in Recent Study by Plus Therapeutics (Exec Edge) -20.89%
08:00AM	EXCLUSIVE: Plus Therapeutics Lead Candidate Shows Preliminary Safety, Efficacy In Type Of Brain Cancer (Benzinga)
06:30AM	Plus Therapeutics Reports ReSPECT-LM Phase 1 Trial Data at the 2023 SNO/ASCO CNS Cancer Conference (GlobeNewswire)
Aug-08-23 04:05PM	Plus Therapeutics to Announce Second Quarter 2023 Financial Results and Host Conference Call on August 14, 2023 (GlobeNewswire) +10.14%
11:22AM	Plus Therapeutics Announces Key Opinion Leader Roundtable on New Clinical Trial Data Being Presented at the 2023 SNO/ASCO CNS Cancer Conference (GlobeNewswire)
Aug-03-23 07:00AM	Plus Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference (GlobeNewswire)
Jul-27-23 05:34PM	Plus Therapeutics Appoints Dr. Pius Maliakal as VP of Clinical Operations (Exec Edge) -9.02% +5.17%
04:05PM	Plus Therapeutics Strengthens Clinical Program with the Appointment of Pius Maliakal as Vice President of Clinical Operations (GlobeNewswire)
07:00AM	Plus Therapeutics to Present at the 2023 SNO/ASCO CNS Cancer Conference (GlobeNewswire)
Jul-13-23 07:00AM	Plus Therapeutics to Present at the 2nd Annual Targeted Radiopharmaceuticals Summit (GlobeNewswire)
Jun-29-23 07:00AM	Plus Therapeutics Reports Positive Interim Updates from Two ReSPECT Clinical Trials at SNMMI Annual Meeting (GlobeNewswire) -5.38%
Jun-14-23 07:00AM	Plus Therapeutics to Participate in the 2023 Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest (GlobeNewswire) -10.68%
Jun-08-23 07:00AM	Plus Therapeutics Announces Participation at Upcoming SNO Pediatric Conference and SNMMI Annual Meeting (GlobeNewswire)
Jun-01-23 07:00AM	Plus Therapeutics Provides Company Update Today (GlobeNewswire)
May-30-23 07:00AM	Plus Therapeutics Announces Topline Results from Recurrent Glioblastoma External Control Analysis at ASCO 2023 (GlobeNewswire) -7.19%
May-25-23 07:00AM	Plus Therapeutics to Present at the 2023 Virtual June Investor Summit (GlobeNewswire)
May-16-23 07:00AM	Plus Therapeutics Regains Compliance with Nasdaq Listing Requirements (GlobeNewswire) -7.09%
May-12-23 07:00AM	Plus Therapeutics to Present in EndBrainCancer Initiative Virtual Educational Event (GlobeNewswire) -8.47%
May-02-23 07:00AM	Plus Therapeutics Expands Collaboration with Piramal Pharma Solutions to Meet Increase in Investigational Drug Demand for Ongoing and Planned Clinical Trials (GlobeNewswire) -7.27%
Apr-28-23 12:55PM	Plus Therapeutics Announces Reverse Stock Split (GlobeNewswire)
Apr-21-23 09:01AM	Q1 2023 Plus Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -13.98%
Apr-20-23 05:25PM	Plus Therapeutics (PSTV) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +5.83%
04:05PM	Plus Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
Apr-19-23 07:00AM	Plus Therapeutics Completes Enrollment of the Original Three Patients Required for Cohort 8 of ReSPECT-GBM Phase 1/2a Trial (GlobeNewswire)
Apr-18-23 04:15PM	Plus Therapeutics to Participate in Panel at the Canaccord Genuity Horizons in Oncology Virtual Conference (GlobeNewswire)
07:00AM	Plus Therapeutics Completes Phase 1/Part A of the ReSPECT-LM Clinical Trial for Leptomeningeal Metastases (GlobeNewswire)
Apr-12-23 07:00AM	Plus Therapeutics to Announce First Quarter 2023 Financial Results and Host Conference Call on April 20, 2023 (GlobeNewswire)

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The firm focuses on the development of chemotherapeutics and radio therapeutics for rare cancers that address unmet medical and market needs. Its products include Rhenium NanoLiposome and DocePLUS. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in Austin, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hawkins Richard J	Director	Sep 13 '24	Buy	1.50	4,000	5,996	15,188	Sep 17 07:00 AM
Hawkins Richard J	Director	Sep 12 '24	Buy	1.35	6,285	8,512	11,188	Sep 16 07:00 AM
Petersen Greg	Director	Sep 11 '24	Buy	1.35	12,500	16,875	48,921	Sep 13 06:04 AM
Clowes Howard	Director	Sep 11 '24	Buy	1.34	5,000	6,681	26,497	Sep 13 06:04 AM
HEDRICK MARC H	Chief Executive Officer	Sep 10 '24	Buy	1.23	8,000	9,839	20,425	Sep 11 06:02 AM
Sims Andrew John Hugh MacIntyr	Chief Financial Officer	Sep 10 '24	Buy	1.27	4,098	5,204	9,815	Sep 11 06:02 AM
Sims Andrew John Hugh MacIntyr	Chief Financial Officer	May 08 '24	Buy	2.04	4,902	10,000	5,717	May 10 07:30 AM
HEDRICK MARC H	Chief Executive Officer	May 08 '24	Buy	2.04	12,255	25,000	12,425	May 10 07:30 AM
Petersen Greg	Director	May 08 '24	Buy	2.04	12,255	25,000	36,421	May 10 07:30 AM
Clowes Howard	Director	May 08 '24	Buy	2.04	9,804	20,000	21,497	May 10 07:30 AM
Hawkins Richard J	Director	May 08 '24	Buy	2.04	4,902	10,000	4,903	May 10 07:30 AM
Lenk Robert P	Director	May 08 '24	Buy	2.04	4,167	8,501	29,327	May 10 07:30 AM

SVRA

Savara Inc

PSTV

Plus Therapeutics Inc

Upgrade your FINVIZ experience